B+
Bull case
30%
Probability
Target price
$48.00
+69.0% vs current
PAHC
Phibro Animal HealthDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$36.00
+26.8% vs current
B-
Bear case
20%
Probability
Target price
$24.00
-15.5% vs current
AI sentiment snapshot
Latest data as of 2026-05-31
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+80.3
Score
AI commentary
Primary-source evidence is constructive: the May 6 release beat on sales, adjusted EPS, and adjusted EBITDA, then raised FY26 guidance and improved liquidity through a larger revolver. The main reason to stay cautious is the newly disclosed Brazil antimicrobial regulatory issue, and the packet does not surface a clean post-print analyst revision chain or a verified market-reaction series, so this is a positive but still monitoring-style setup rather than a high-conviction rerate.
RankAlpha Sentiment Codex - 2026-05-31
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-06eventQ3 beat and FY26 guidance raise improved the near-term setupMedium impact
The May 6 release showed third-quarter net sales of $383.5M (+10%), adjusted EBITDA of $60.8M (+11%), adjusted diluted EPS of $0.76 (+19%), and an FY26 guide increase to $1.46B-$1.50B of sales and $247M-$255M of adjusted EBITDA, which is the core positive re-rating input [#8-K-2026-05-06].
2026-05-06catalystBrazil antimicrobial regulatory change is the main near-term overhangMedium impact
Management also flagged a post-quarter Brazil regulatory framework change affecting certain antimicrobial products, creating a short-term mix and margin question until the revenue exposure and remediation path are clearer [#8-K-2026-05-06].
2026-06-30catalystFY26 execution and cash conversion must confirm the higher outlookHigh impact
The expanded revolver capacity to $435M, $77.5M of cash and short-term investments, and 3.1x gross leverage make the balance sheet workable, but the long case still depends on converting the raised FY26 outlook into sustained cash generation by fiscal year-end [#8-K-2026-05-06].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-31 • Updated nightlySource: Internal modelMethodology